Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72879
Title:
Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.
Authors:
O'Connor, James P B; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Jackson, Alan; Ghiorghiu, Dana; Carrington, Bernadette M; Rose, Chris J; Mills, Samantha J; Swindell, Ric; Roberts, Caleb; Mitchell, Claire L; Parker, Geoff J M
Abstract:
PURPOSE: To define a simple radiologic biomarker of prognosis in patients with advanced epithelial ovarian carcinoma on first-line chemotherapy. EXPERIMENTAL DESIGN: Twenty-seven patients receiving platinum-based chemotherapy with >2 cm residual disease [International Federation of Gynecology and Obstetrics (FIGO) stages IIIC or IV] after surgery were identified. The proportion of enhancing tumor tissue--the enhancing fraction--was calculated on pre-chemotherapy computed tomography scans at four Hounsfield unit (HU) thresholds and assessed for correlation with CA125 response, Response Evaluation Criteria in Solid Tumors (RECIST) radiologic response, and time to progression. Discriminative power was assessed by leave-one-out discriminant analysis. RESULTS: Pre-chemotherapy residual tumor volume did not correlate with clinical outcome. Pre-chemotherapy enhancing fraction at all thresholds significantly correlated with CA125 response (P < 0.001, rho = 0.553 for 50 HU; P < 0.001, rho = 0.565 for 60 HU; P < 0.001, rho = 0.553 for 70 HU; P = 0.001, rho = 0.516 for 80 HU). Significant correlations were also shown for radiologic response at all thresholds. Enhancing fraction predicted CA125 response with 81.9% to 86.4% specificity and Response Evaluation Criteria in Solid Tumors response with 74.9% to 76.8% specificity at 95% sensitivity (dependent on threshold). Enhancing fraction correlated with time to progression at the 60 HU (P = 0.045, rho = 0.336) and 70 HU (P = 0.042; rho = 0.340) thresholds. CONCLUSION: Pre-chemotherapy enhancing fraction is a simple quantitative radiologic measure. Further evaluation in larger trials is required to confirm the potential of enhancing fraction as a predictive factor, particularly for patients who may benefit from the addition of antiangiogenic therapy.
Affiliation:
Imaging Science and Biomedical Engineering, University of Manchester, Manchester, UK. james.o'connor@manchester.ac.uk
Citation:
Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. 2007, 13 (20):6130-5 Clin. Cancer Res.
Journal:
Clinical Cancer Research
Issue Date:
15-Oct-2007
URI:
http://hdl.handle.net/10541/72879
DOI:
10.1158/1078-0432.CCR-07-0331
PubMed ID:
17947478
Type:
Article
Language:
en
ISSN:
1078-0432
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, James P B-
dc.contributor.authorJayson, Gordon C-
dc.contributor.authorJackson, Alan-
dc.contributor.authorGhiorghiu, Dana-
dc.contributor.authorCarrington, Bernadette M-
dc.contributor.authorRose, Chris J-
dc.contributor.authorMills, Samantha J-
dc.contributor.authorSwindell, Ric-
dc.contributor.authorRoberts, Caleb-
dc.contributor.authorMitchell, Claire L-
dc.contributor.authorParker, Geoff J M-
dc.date.accessioned2009-07-07T16:19:44Z-
dc.date.available2009-07-07T16:19:44Z-
dc.date.issued2007-10-15-
dc.identifier.citationEnhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. 2007, 13 (20):6130-5 Clin. Cancer Res.en
dc.identifier.issn1078-0432-
dc.identifier.pmid17947478-
dc.identifier.doi10.1158/1078-0432.CCR-07-0331-
dc.identifier.urihttp://hdl.handle.net/10541/72879-
dc.description.abstractPURPOSE: To define a simple radiologic biomarker of prognosis in patients with advanced epithelial ovarian carcinoma on first-line chemotherapy. EXPERIMENTAL DESIGN: Twenty-seven patients receiving platinum-based chemotherapy with >2 cm residual disease [International Federation of Gynecology and Obstetrics (FIGO) stages IIIC or IV] after surgery were identified. The proportion of enhancing tumor tissue--the enhancing fraction--was calculated on pre-chemotherapy computed tomography scans at four Hounsfield unit (HU) thresholds and assessed for correlation with CA125 response, Response Evaluation Criteria in Solid Tumors (RECIST) radiologic response, and time to progression. Discriminative power was assessed by leave-one-out discriminant analysis. RESULTS: Pre-chemotherapy residual tumor volume did not correlate with clinical outcome. Pre-chemotherapy enhancing fraction at all thresholds significantly correlated with CA125 response (P < 0.001, rho = 0.553 for 50 HU; P < 0.001, rho = 0.565 for 60 HU; P < 0.001, rho = 0.553 for 70 HU; P = 0.001, rho = 0.516 for 80 HU). Significant correlations were also shown for radiologic response at all thresholds. Enhancing fraction predicted CA125 response with 81.9% to 86.4% specificity and Response Evaluation Criteria in Solid Tumors response with 74.9% to 76.8% specificity at 95% sensitivity (dependent on threshold). Enhancing fraction correlated with time to progression at the 60 HU (P = 0.045, rho = 0.336) and 70 HU (P = 0.042; rho = 0.340) thresholds. CONCLUSION: Pre-chemotherapy enhancing fraction is a simple quantitative radiologic measure. Further evaluation in larger trials is required to confirm the potential of enhancing fraction as a predictive factor, particularly for patients who may benefit from the addition of antiangiogenic therapy.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectTumour Markersen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma-
dc.subject.meshFalse Positive Reactions-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshModels, Biological-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshSensitivity and Specificity-
dc.subject.meshTreatment Outcome-
dc.subject.meshTumor Markers, Biological-
dc.titleEnhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.en
dc.typeArticleen
dc.contributor.departmentImaging Science and Biomedical Engineering, University of Manchester, Manchester, UK. james.o'connor@manchester.ac.uken
dc.identifier.journalClinical Cancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.